PARP1 and pancreatic neoplasm: Interestingly, in three pancreatic cancer cell lines (Su.86.86, MIA Paca-2, T3M-4) treated with vorinostat or CUDC-101, a small molecule that simultaneously inhibits epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and subsequently irradiated after 24 h, increased the radiation sensitivity of pancreatic tumor cell lines in a dose-dependent manner, reduced proliferation and clonogenic survival, and increased radiation-induced apoptosis (diminished full length Poly (ADP-ribose) polymerase [PARP-1]) [136].